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 2 
Abstract 30 
The role of the transcription factors SREBP-1a and SREBP-1c in the regulation of 31 
cholesterol and fatty acid metabolism has been well studied, however little is known 32 
about their specific function in muscle. In the present study, analysis of recent 33 
microarray data from muscle cells overexpressing SREBP1 suggested that they may 34 
play a role in the regulation of myogenesis. We then demonstrated that SREBP-1a 35 
and -1c inhibit myoblast to myotube differentiation, and also induce in vivo and in 36 
vitro muscle atrophy. Furthermore, we have identified the transcriptional repressors 37 
BHLHB2 and BHLHB3 as mediators of these effects of SREBP-1a and -1c in muscle. 38 
Both repressors are SREBP-1 target genes, and they affect the expression of 39 
numerous genes involved in the myogenic program. Our findings identify a new role 40 
for SREBP-1 transcription factors in muscle, thus linking the control of muscle mass 41 
to metabolic pathways. 42 
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Introduction 43 
The Sterol Regulatory Element Binding Proteins (SREBP) transcription factors 44 
belong to the basic helix-loop-helix leucine zipper family of DNA binding proteins. 45 
The three isoforms identified so far in mammalian tissues are coded by two distinct 46 
genes, Srebf1 and Srebf2, and vary in structure, regulation, and functions (14). 47 
SREBP-1a and SREBP-1c proteins are produced by alternative promoter usage of 48 
the SREBF1 gene and are key actors of the regulation of genes related to lipid 49 
metabolism, especially those involved in lipogenesis and triglyceride deposition. In 50 
contrast, SREBP-2 has been more closely associated to cholesterol synthesis and 51 
accumulation (20, 52).  52 
In agreement with these known functions, the SREBP-1 proteins are strongly 53 
expressed in tissues with high lipogenic capacities, like liver and adipose tissues. 54 
However, significant expression has been also reported in skeletal muscle, both in 55 
vivo and in vitro in cultured muscle cells (12, 13, 18). In muscle, SREBP-1 expression 56 
is induced by activation of the PI3K/Akt and the MAP kinase pathways by insulin and 57 
growth factors (6, 12, 18, 28, 38), suggesting additional functions of these 58 
transcription factors in a tissue with a low rate of lipid synthesis. Using microarray 59 
analysis to characterize the role of SREBP-1a and -1c in skeletal muscle, we have 60 
recently identified some of their potential target genes in primary cultures of human 61 
myotubes overexpressing SREBP-1a or SREBP-1c (43). In this study we found that 62 
SREBP-1a and -1c regulate more than one thousand genes, indicating that they are 63 
potentially involved in the regulation of a large variety of biological functions in 64 
muscle cells. Quite unexpectedly, we observed a dramatic reduction in the 65 
expression of a number of muscle-specific genes and markers of muscle 66 
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differentiation in cells overexpressing SREBP-1 proteins. This led us to investigate 67 
their potential role in the regulation of myogenesis and muscle development. 68 
The early stages of muscle development are regulated by muscle-specific 69 
basic helix-loop-helix transcription factors (e.g. MYF5, MYOD1, MYOG (myogenin) 70 
and MYF6 (MRF4)), which are also involved in the differentiation of satellite cells 71 
during regeneration process in adult muscle. Recently, the transcriptional factor 72 
BHLHB3 was shown to inhibit in vitro muscle cell differentiation by interacting with 73 
MYOD1 (2). BHLHB3 (also named DEC1/SHARP1) is a transcriptional repressor 74 
closely related (97% homology in amino acid sequence in the bHLH domain) to 75 
BHLHB2 (also named Stra13/DEC2/SHARP2). They both repress the expression of 76 
target genes by binding to E-Box sequences as well as through protein-protein 77 
interactions with other transcription factors (review in (51)). BHLHB2 and BHLHB3 78 
genes are widely expressed in both embryonic and adult tissues and their expression 79 
is regulated in cell type-specific manner in various biological processes, including 80 
circadian rhythms (19), hypoxia (35) or cellular differentiation (7). Their involvement 81 
in the regulation of developmental processes during embryogenesis has been largely 82 
studied (4, 7, 24, 34, 44). We demonstrate here that BHLHB2 and BHLHB3 mediate 83 
negative effects of SREBP-1 transcription factors on myogenesis, acting both at the 84 
myoblast and myotube stages. The SREBP-1 mediated effects on BHLHB2 and 85 
BHLHB3 activity thus defines a novel negative regulation pathway in skeletal muscle 86 
cell development. 87 
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Materials and Methods 88 
 89 
Culture of human skeletal muscle cells. Muscle biopsies were taken from healthy 90 
lean subjects during surgical procedure, with the approval of the Ethics Committee of 91 
Lyon Hospitals. Myoblasts were purified and differentiated myotubes were prepared 92 
according to the procedure previously described in detail (11). 93 
 94 
Expression vectors and generation of recombinant adenoviruses. For the 95 
construction of expression vector encoding BHLHB2, a verified sequence I.M.A.G.E. 96 
clone (cloneID 4860809) was purchased from Geneservice (Cambridge, UK) and 97 
subcloned into the pcDNA 3.1 expression vector (Invitrogen). The expression vector 98 
encoding BHLH3 was generated by PCR amplification and ligated into PCDNA3.1. 99 
Expression vector encoding the dominant-negative form of SREBP-1 (ADD1-DN) is a 100 
generous gift of Dr. B. Spiegelman (Dana-Farber Cancer Institute/Harvard Medical 101 
School, Boston, USA) (27). Recombinant adenoviral genomes carrying the human 102 
BHLHB2 or BHLHB3 or ADD1-DN were generated by homologous recombination in 103 
the VmAdcDNA3 plasmid (a gift from Dr S. Rusconi, Fribourg, Switzerland) and 104 
amplified as described previously (9, 12).  105 
 Construction of expression vectors encoding mature nuclear forms of human 106 
SREBP-1a (named pCMV-hSREBP1a) and SREBP-1c (named pCMV-hSREBP1c) 107 
was described previously (12). A fragment of the pIRES plasmid (Clontech, Montain 108 
View, CA, USA) containing the IRES and EGFP sequence was cloned into pCMV-109 
hSREBP1a and pCMV-hSREBP1c to obtain pCMV-hSREBP1a-IRES-GFP and 110 
pCMV-hSREBP1c-IRES-GFP. Recombinant adenoviruses expressing 111 
simultaneously nuclear form of either SREBP-1a or SREBP-1c and GFP as a 112 
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marker, were generated by homologous recombination in the VmAdcDNA3 plasmid 113 
and amplified. 114 
 115 
Overexpression of Human SREBP-1a, SREBP-1c, BHLHB2 or BHLHB3 in 116 
human muscle cells. The construction of recombinant adenoviruses encoding 117 
nuclear SREBP-1a and SREBP-1c was described previously (12). Human muscles 118 
cells were infected as myoblasts or myotubes. Myoblasts were grown in six-well 119 
plates. Myoblasts at 70% confluence, or myotubes after 5 days of differentiation, 120 
were infected for 48 h with the recombinant adenovirus encoding BHLHB2 or 121 
BHLHB3 or nuclear forms of SREBP-1a or SREBP-1c, or GFP as a control.  122 
 123 
Inhibition of BHLHB2 and BHLHB3 expression in human muscle cells.  Inhibition 124 
of BHLHB2 and BHLHB3 expression was performed by RNA interference using small 125 
interfering RNA (siRNA) against BHLHB2 and against BHLHB3 (Qiagen). A 126 
rhodamine labeled GFP-22 siRNA was used as control. Myoblasts at 70% 127 
confluence were transfected with siRNAs using the Hiperfect transfection reagent 128 
(Qiagen, Courtaboeuf, France), according to the manufacturers protocol.  129 
 130 
In vivo overexpression of Human SREBP-1a, SREBP-1c, BHLHB2, BHLHB3 in 131 
mice tibialis anterior muscles. All animal procedures were conducted according to 132 
the national guidelines for the care and use of laboratory animals. Adult (12-14 week-133 
old) BALB/c male mice (Harlan, France) were subjected to adenoviral delivery 134 
according to the procedure described by Sapru et al. (45). Briefly, right Tibialis 135 
Anterior muscles of mice were injected with 1010 infectious unit of recombinant 136 
adenovirus expressing either SREBP-1a/GFP, SREBP-1c/GFP, BHLHB2 or 137 
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BHLHB3. As a control, the contralateral tibialis anterior muscles were also injected 138 
with 1010 infectious units of recombinant adenovirus expressing GFP. Mice were 139 
sacrificed seven days after injection. Tibialis anterior muscle was removed and 140 
immediately snap-frozen in liquid nitrogen. Ten-micron sections were cut and every 141 
tenth section collected onto glass slides for examination under fluorescence 142 
illumination using an Axiovert 200 microscope, an Axiocam MRm camera and 143 
Axiovision 4.1 image acquisition software (Carl Zeiss, Göttingen, Germany). Muscle 144 
fibers size and fluorescence intensity were measured using NIH ImageJ software. 145 
 146 
Protein expression analysis by immunocytofluorescence. Cells were fixed in 147 
10% formaldehyde  and permeabilized with 0.1% Triton X-100. Non specific binding 148 
sites were blocked with 1% bovine serum albumin in PBS 1X for 1hour at room 149 
temperature. Cells were then incubated overnight at 4°C with specific primary 150 
antibodies (anti- TNNI1, C-19; Santa Cruz Biotechnology, Santa Cruz, CA, USA; anti-151 
myogenin, F5D; Developmental Studies Hybridoma Bank, University of Iowa, Iowa 152 
City, IA). Detection was achieved using Alexa 555 donkey anti-goat and goat anti-153 
mouse IgG (Molecular Probes, Invitrogen). 154 
Cells were mounted with Vectashield with DAPI Fluoprep mounting medium (H1200; 155 
Vector Laboratories, Peterborough, England) and examined by fluorescence 156 
microscopy with an Axiovert 200 microscope, an Axiocam MRm camera and 157 
Axiovision 4.1 image acquisition software (Carl Zeiss, Göttingen, Germany). Area of 158 
TNNI1 immunostained differentiated myotubes was measured using NIH ImageJ 159 
software. 160 
  161 
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Protein expression analysis by Western Blotting. Classical western-blot 162 
experiments were performed according to (12). After transfer, gels were stained with 163 
Coomassie Blue. Membranes were then incubated overnight at 4°C with the following 164 
specific primary antibodies : anti-SREBP1 (H160), anti-MYOD1 (M316), anti-MEF2C 165 
(E17), anti-MYOG (M225), anti-TNNI1 (C-19), and anti-TNNI2 (C-19) from Santa 166 
Cruz Biotechnology, (Santa Cruz, CA, USA) ; anti-BHLHB2 (M01; 5B1) and anti-167 
BHLHB3  from Abnova (M01; 4H6) (Taipei, Taiwan). 168 
The signal was detected using a horse-radish peroxidase-conjugated secondary 169 
antibody and revealed with the enhanced chemiluminescence system (Pierce, 170 
Rockford, IL, USA). Signal was quantified using NIH ImageJ software. Intensity of 171 
Coomassie Blue staining was used to normalize the total amount of proteins. 172 
 173 
Quantification of mRNAs by real-time RT-PCR. Total RNA was isolated using the 174 
Trizol reagent (Invitrogen, Courtaboeuf, France) according to manufacturer’s 175 
instructions. First-strand cDNAs were synthesized from 500 ng of total RNAs in the 176 
presence of 100 U of Superscript II (Invitrogen) and a mixture of random hexamers 177 
and oligo(dT) primers (Promega). Real-time PCR assays were performed with Rotor-178 
GeneTM 6000 (Corbett Research, Mortlake, Australia). A list of the primers and real-179 
time PCR assay conditions are available upon request (lefai@univ-lyon1.fr). The 180 
results were normalized using RPLP0 or HPRT mRNA concentration, measured as 181 
reference gene in each sample. 182 
 183 
Chromatin immuno-precipitation (ChIP) assay. The ChIP experiments were 184 
performed as previously described (43) using the ChIP It Express Enzymatic Kit from 185 
Active Motif (Rixensart, Belgium), according to the manufacturer’s instructions. ChIP 186 
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products were analyzed by quantitative and classical PCR using specific primers for 187 
BHLHB2 and BHLHB3 promoter (PCR primers are available on request).  188 
 189 
Construction of reporter plasmids, and BHLHB2 and BHLHB3 promoter 190 
activity. A human genomic clone (NR5-IH18RS) which contains NotI flanking regions 191 
corresponding to the BHLHB2 promoter was obtained from Pr. E. R. Zabarovsky 192 
(Microbiology and Tumour Biology Center and Center  for Genomics and  193 
Bioinformatics, Karolinska Institute, Stockholm, Sweden) (Zabarovsky ER, 2000). 194 
The -408/+75 (according to the transcription starting site) fragment was then 195 
subcloned into the luciferase reporter gene vector pGL3-Enhancer (Promega) to 196 
obtain pB21 (-408/+75). The -951/-407 fragment was generated by PCR and ligated 197 
into pB21 to obtain pB22 (-951/+75). The constructs pB23 (-264/+75) and pB26 (-198 
187/+75) were generated by deletion of pB21. To obtain pB32, two genomic 199 
fragments, corresponding to the -940/-289 and -524/+238 regions of the BHLHB3 200 
gene, were generated by PCR and combined to obtain the –940/+238 fragment into 201 
pGL3-E vector.  Mutations of the SRE motifs were performed as described (12). 202 
Mutagenesis was performed to replace bases 2, 4 and 6 of each identified SRE by 203 
thymidine residues (Quick Change Mutagenesis Kit, Qiagen). 204 
Transfection studies were carried out on myoblasts or myotubes plated in 12-well 205 
plates as previously described (12). Firefly and Renilla luciferase activities (Dual 206 
luciferase reporter assay system; Promega) were measured using a Centro LB 960 207 
Luminometer (Berthold Technology, Thoiry, France). 208 
 209 
Microarray analysis of myotubes overexpressing BHLHB2 and BHLHB3. The 210 
procedure used to obtain and analyze microarray data has previously been described 211 
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(43). Briefly, Total RNA extracted from BHLHB2 and BHLHB3 overexpressing 212 
myotubes were hybridized on oligonucleotide microarrays produced by the French 213 
Genopole Network (RNG) consisting of 25,342 oligonucleotides of 50-mers printed 214 
on glass slides. Only spots with recorded data on the 8 slides (4 for BHLHB2 and 4 215 
for BHLHB3) were selected for further analysis. With these selection criteria, 12,825 216 
spots were retrieved. Data were analyzed using the one-class significance analysis 217 
of microarray (SAM) procedure. Microarrays data are available in the GEO database 218 
under number GSE12947 and following the link: 219 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi.  220 
 221 
 222 
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Results 223 
SREBP-1a and -1c down-regulate muscle specific genes in human myotubes  224 
We recently reported that adenovirus-mediated expression of the mature nuclear 225 
forms of either SREBP-1a or SREBP-1c triggered the regulation of more than 1300 226 
genes in human differentiated myotubes (43). Using FATiGO (www.babelomics.es) 227 
to analyze these microarray data, three Gene Ontology (GO) classes showed 228 
significant over-representation in the list of genes found to be regulated in the 229 
presence of SREBP-1 proteins when compared to their representation in the human 230 
genome: “muscle contraction” (GO 0006936, adjusted p value = 2.84 e-5), the 231 
subclass “striated muscle contraction” (GO 0006941, adjusted p value = 2.46 e-5) 232 
and “muscle development” (GO 0007517, adjusted p value = 6.27 e-5). The 233 
corresponding genes with fold-change values upon SREBP-1a or -1c expression are 234 
listed in Table 1. These genes encode transcription factors involved in muscle 235 
differentiation (i.e. MYOD1, MYOG, MEF2C), as well as a large number of muscle 236 
contraction proteins (i.e. heavy and light chains of myosin, troponins, titin). Most of 237 
them were down-regulated in the presence of SREBP-1a or -1c (28 of 38 for “muscle 238 
contraction” and 26 of 39 for “muscle development”).  239 
 240 
Transcriptional repressors BHLHB2 and BHLHB3 are SREBP-1 target genes 241 
The SREBP-1s microarray data obtained on differentiated myotubes contain two 242 
bHLH family members that are up regulated upon SREBP-1s overexpression. The 243 
transcriptional repressors BHLHB2 and BHLHB3 show an about 2-fold increase in 244 
their expression levels (supplementary data of (43)). Since recent report indicated 245 
that BHLHB3 is a potent inhibitor of muscle cell differentiation (2), we decided to 246 
focus on these factors. To assess SREBP-1a and –1c effects on BHLHB2 and 247 
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BHLHB3 expression, we overexpressed nuclear SREBP-1 in human primary muscle 248 
cells at both myoblasts and myotubes stages, and also in vivo in mouse tibialis 249 
anterior muscle. As shown in figure 1A and 1B, overexpression of SREBP-1 in 250 
myoblasts, myotubes and mouse muscle induced significant increases in both 251 
BHLHB2 and BHLHB3 mRNA and proteins levels in all situations. As a control, we 252 
verified that overexpression of ADD1-DN, a dominant-negative mutant of SREBP-1 253 
(27), does not significantly affects BHLHB2 and BHLHB3 expression levels in 254 
cultured muscle cells. 255 
 256 
The promoter sequences of the human BHLHB2 and BHLHB3 genes contain 257 
putative SRE motifs for SREBP-1 binding (located at -839/-830 and –32/-23 for 258 
BHLHB2; -651/-642 and +43/+52 for BHLHB3 relative to the respective transcription 259 
start sites). Additionally, a degenerate motif was identified at –248/-238 260 
(TCACAGGGT) in the BHLHB2 promoter. To investigate whether SREBP-1a and -1c 261 
increase BHLHB2 and BHLHB3 expression through promoter activation, we 262 
performed gene reporter experiments in muscle and non-muscle cell lines transiently 263 
transfected with SREBP-1a/-1c expressing plasmids. Measurements of luciferase 264 
activities confirm that overexpression of SREBP-1 proteins strongly increases both 265 
BHLHB2 and BHLHB3 promoters activities in myoblasts, myotubes and non muscle 266 
HepG2 cells (Figure 2 A and B, left). Activation of the promoters in non-muscle cells 267 
excluded the participation of additional muscle-specific factors in the induction of 268 
BHLHB2 and BHLHB3 by SREBP-1 proteins. To assess the involvement of the 269 
identified putative SREs in both promoters, we performed mutations and deletions of 270 
the various sites (Figure 2 A and B, right). Concerning the BHLHB2 promoter, 271 
deletion of the distal motif as well as mutation of the proximal motif did not modify 272 
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enhancement of promoter activity by SREBP-1 proteins, whereas the deletion of the 273 
SRE-like motif suppressed SREBP-1 activation. Concerning the BHLHB3 promoter, 274 
mutation of either distal or proximal SREs suppressed promoter activation, showing 275 
that they are both are involved in the response to SREBP-1. Finally, chromatin 276 
immunoprecipitation (ChIP) experiments further confirmed that SREBP-1 proteins 277 
directly bind the BHLHB2 and BHLHB3 promoters (Figure 2C).  278 
We then conclude that transcriptional repressors BHLHB2 and B3 are new direct 279 
target genes of SREBP-1, the expression of which is increased by SREBP-1 binding 280 
on their promoters.  281 
 282 
Overexpression of BHLHB2and BHLHB3 in myotubes 283 
We performed microarray analysis in human primary myotubes overexpressing either 284 
BHLHB2 or BHLHB3 after adenovirus infection. FATIGO analysis revealed that the 285 
same biological processes identified after SREBP-1 overexpression (“muscle 286 
contraction”, “striated muscle contraction” and “muscle development”) were 287 
significantly enriched (adjusted p values < 0.05) in the lists of regulated genes. We 288 
found that BHLHB2 and BHLHB3 down-regulated 69 and 65 genes with muscle 289 
annotation, respectively (Table 2). Furthermore, the comparison with the SREBP-1 290 
microarray data showed that a large proportion (34%) of the muscle-specific genes 291 
that were down-regulated by SREBP-1 expression were also down-regulated by 292 
BHLHB2/B3 overexpression.  293 
Overlapping down-regulated genes for the two GO biological processes ”muscle 294 
development” and “muscle contraction” are represented in Figure 3. Among genes 295 
involved in muscle differentiation, MYOD1, MYOG and MEF2C show a decrease in 296 
their expression upon both SREBP-1 and BHLHB2/B3 overexpression. 297 
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  298 
SREBP-1a and -1c  inhibit myoblast differentiation  299 
Because the expression of specific markers of muscle differentiation was decreased 300 
in myotubes overexpressing SREBP-1, we first examined the expression of the four 301 
studied transcription factors during the differentiation of human primary muscle cells 302 
(Figure 4 A). All four present a similar pattern of expression with an increase during 303 
proliferation and a decrease after induction of differentiation. To further examine 304 
whether SREBP-1 could directly affect myogenic differentiation, primary human 305 
myoblasts were thus infected with recombinant adenoviruses expressing GFP, 306 
SREBP-1a, or SREBP-1c. After 48 hours, SREBP-1 expressing myoblasts showed a 307 
dramatic decrease in MYOD1, MYOG and MEF2C levels (Figure 4B). When the cells 308 
were induced to differentiate (medium change and serum starvation) for five days, 309 
only Ad-GFP infected cells underwent differentiation (Figure 4C). The presence of 310 
SREBP-1 totally blocked the differentiation of myoblasts into myotubes.  311 
To determine the implication of BHLHB2 and/or BHLHB3 in this process, human 312 
primary myoblasts were infected with recombinant adenovirus expressing either 313 
BHLHB2 or BHLHB3. As shown in Figure 4D, 48 hours of BHLHB2 and BHLHB3 314 
overexpression also induced a marked decrease in the expression of muscle 315 
regulatory factors (MYOD1, MYOG and MEF2C). After 5 days of differentiation, we 316 
observed a dramatic decrease in the number and the size of polynucleated cells, 317 
correlated with the reduced expression of myogenin and troponin (figure 4E).  318 
To finally demonstrate the involvement of BHLHB2 and BHLHB3 in the effects of 319 
SREBP-1 on myoblasts, SREBP-1 overexpressing myoblasts were transfected with 320 
siRNA against GFP (control), BHLHB2, or BHLHB3, resulting in a partial gene 321 
extinction of BHLHB2 and BHLHB3 expression (Figure 5A). As shown in Figure 5B, 322 
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inhibition of either BHLHB2 or BHLHB3 can restore, at least partially, the expression 323 
of MYOD1, MYOG and MEF2C proteins that are down-regulated upon SREBP-1 324 
overexpression. Depletion of BHLHB2/B3 was sufficient to restore differentiation and 325 
myogenin and troponin expression in cells overexpressing SREBP-1 (Figure 5C). 326 
Altogether, these data led us to propose that SREBP-1a and -1c block myoblasts to 327 
myotubes differentiation via an increase in BHLHB2 and BHLHB3 expression, the 328 
latter repressing the expression of MRFs. 329 
 330 
SREBP-1a and -1c induce atrophy of differentiated myotubes 331 
We next examined the consequences of nuclear accumulation of SREBP-1 proteins 332 
in differentiated muscle cells. To confirm and expand the microarray data, we 333 
measured the expression levels of several transcription factors and sarcomeric 334 
protein genes using quantitative PCR in primary myotubes overexpressing the 335 
SREBP-1 factors for 48 hours. Figure 6 shows that both SREBP-1a and 1c 336 
decreased the expression of myogenic regulatory factors (MYOD1, MYOG, and 337 
MEF2C) (Figure 6A). A significant reduction in the mRNA levels of muscle contractile 338 
proteins (TTN, TNNI1, TNNI2, and MYL1) was also observed. These data were 339 
further confirmed at the protein level (Figure 6B). Therefore, the mature forms of 340 
SREBP-1a and -1c clearly induced a dramatic decrease in the expression of major 341 
actors of skeletal muscle function, involved in either formation or contractility.  342 
Direct observation of myotubes overexpressing SREBP-1 showed a decrease in cell 343 
surfaces. Troponin immunostaining confirmed a considerable reduction in sarcomeric 344 
protein content (Figure 6C). Cell sizes measurements showed that SREBP-1 proteins 345 
induced an approximately 6-fold decrease in cell surface (Figure 6D). These 346 
observations indicated thus that nuclear accumulation of SREBP-1 led to myotube 347 
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atrophy, with a severe decrease in the expression of muscle regulatory factors and 348 
sarcomeric proteins. To assess whether the observed SREBP1-induced atrophy 349 
involved known atrophic factors, we measured the mRNA levels of FBXO32 350 
(Atrogin1), SMURF1 (MuRF-1/TRIM63) and FOXO1. As shown in Figure 6A, with the 351 
exception of SMURF1, the expression of these factors was reduced in the presence 352 
of SREBP-1a and -1c. The up-regulation of SMURF1 mRNA however, is in 353 
agreement with our previous microarray data (43). 354 
 355 
As observed with SREBP-1a and -1c, infection of fully differentiated myotubes with 356 
adenoviruses expressing BHLHB2 or BHLHB3 strongly repressed the expression of 357 
myogenic factors (MYOD1, MYOG, and MEF2C) and sarcomeric proteins (MYL1, 358 
TNNI1, and TTN) (Figure 7A). Overexpression of BHLHB2 and BHLHB3 also 359 
provoked the atrophy of muscle cells (Figure 7B), as evidenced by cell size 360 
measurements indicating a greater than 60% reduction in myotube areas (Figure 361 
7C). However, in contrast to SREBP-1, BHLHB2 and BHLHB3 overexpression 362 
induced a marked decrease in SMURF1 expression level (Figure 7A).  363 
To confirm the involvement of BHLHB2 and BHLHB3 in the atrophic effect of 364 
SREBP-1 on differentiated myotubes, SREBP-1 overexpressing myotubes were 365 
transfected with siRNA against GFP, BHLHB2, or BHLHB3. As shown in Figure 7D, 366 
gene extinction of either BHLHB2 or BHLHB3 restores the expression of troponin. 367 
Depletion of BHLHB2/B3 also restored, at least partially, the size of myotubes, with a 368 
greater effect of BHLHB3 silencing (Figure 7E). 369 
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 370 
Altogether, these data indicated that, as observed for inhibition of myoblast 371 
differentiation, the transcriptional repressors BHLHB2 and BHLHB3 are directly 372 
involved in the atrophy induced by SREBP-1 in differentiated myotubes.  373 
 374 
SREBP-1a and -1c promote skeletal muscle atrophy in vivo 375 
To investigate the effects of SREBP-1 factors on muscle phenotype in vivo, we 376 
overexpressed SREBP-1a or SREBP-1c in limb muscle of mice using recombinant 377 
adenovirus. Adenoviruses expressing either GFP only, or both SREBP-1a and GFP 378 
(or SREBP-1c and GFP) were generated using dual expression properties of 379 
constructs containing an IRES element (26). Twelve week-old BALB/c male mice 380 
were separated into two groups and adenoviral suspensions were injected in tibialis 381 
anterior muscle with 1010 infectious units of recombinant adenoviruses expressing 382 
only GFP (Ad-GFP) in the left limb of all animals and either SREBP-1a and GFP (Ad-383 
1a/GFP, first group) or SREBP-1c and GFP (Ad-1c/GFP, second group) in the right 384 
limb. Animals were sacrificed seven days after injections and tibialis anterior muscles 385 
were removed for analysis. When comparing the two groups, no differences were 386 
found in GFP-only expressing muscles of the left limbs (weight, fiber sizes, and 387 
fluorescence intensity); we thus considered the data concerning Ad-GFP infected 388 
muscles as a unique set. As shown in Figure 8A, tibialis anterior weight showed a 389 
significant decrease of 17.5% (SREBP-1a/GFP vs. GFP, n=7, p=0.001) and 18.6% 390 
(SREBP-1c/GFP vs. GFP, n=7, p= 0.002) when expressing either of the SREBP-1 391 
proteins. When performing similar experiment with intramuscular injection of 392 
recombinant adenoviruses overexpressing either BHLHB2 or BHLHB3, muscle 393 
weight showed a decrease of 17.1 % (BHLHB2 vs. GFP, n=7, p=0.001) and 24,8 % 394 
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(BHLHB3 vs. GFP, n=7, p=0.001) respectively (Figure 8A).  We next examined fiber 395 
size in histological sections of treated muscles. Quantitative analysis revealed a 396 
significant decrease in average cross-sectional area (CSA) of myofibers for both 397 
SREBP-1a (mean ± SEM = 1998.3 ± 19.7 µm2) and SREBP-1c (mean ± SEM 398 
=1950.2 ± 21.0 µm2) compared to GFP (mean ± SEM = 2378.6 ± 21.7 µm2, p<0.001 399 
for both) (Figure 8B). Size distribution of muscle fiber CSA was different between 400 
GFP-only and SREBP-1/GFP expressing muscles, the latter presenting a marked 401 
displacement of distribution towards smaller sizes of fibers (Figure 8C). 402 
Representative histological sections are shown in Figure 8D with the expected 403 
mosaic pattern of fluorescence. Because of the dual expression strategy, 404 
fluorescence intensities in the muscle fibers of the right limbs reflect the level of 405 
expression of the SREBP-1 recombinant proteins. We therefore examined fiber CSA 406 
as a function of the fluorescence distribution (Figure 8E). While uninfected fibers 407 
(lowest fiber fluorescence category) showed similar myofiber CSA means, the 408 
reduction in mean fiber CSA of Ad-1a/GFP and Ad-1c/GFP infected fibers increased 409 
with fluorescence intensity, reaching a maximum around 20% reduction of mean 410 
CSA when compared to Ad-GFP infected fibers.  411 
 412 
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Discussion  413 
SREBP-1a and SREBP-1c are bHLH transcription factors first identified as 414 
adipocyte determination and differentiation factors (49). Their functions have been 415 
extensively studied in hepatocytes and in mouse liver. By activation of specific target 416 
genes involved in lipogenesis, SREBP-1 increase triglycerides synthesis, and to a 417 
lesser extent cholesterol synthesis (8, 20, 21, 47). SREBP-1c was also shown to 418 
mediate the action of insulin on the expression of lipogenic genes in liver (16). 419 
SREBP-1 proteins are also expressed in skeletal muscle (13, 38, 39) and in cultured 420 
muscle cells (12, 18). In this report we identified a new role for these transcription 421 
factors and demonstrated that both SREBP-1a and SREBP-1c can block myoblast to 422 
myotube differentiation, and also induce myotube atrophy in vitro and in vivo.  423 
The results of the present study also demonstrate that the transcriptional 424 
repressors BHLHB2 and BHLHB3 are SREBP-1 target genes and that they mediate 425 
the observed SREBP-1 action on human muscle cell. Both BHLHB2 and BHLHB3 426 
have been involved in the regulation of differentiation and growth of several cell 427 
types. BHLHB2 promotes the differentiation of trophoblast stem cells to trophoblast 428 
giant cells (22), induces neuronal differentiation of pheochromocytoma P19 cell (7) 429 
and promotes chondrocyte differentiation of ATDC5 cells (46). BHLHB2 can also 430 
block adipocyte differentiation through direct transcriptional repression of 431 
PPARgamma gene expression (53). Concerning muscle cells, BHLHB2 is expressed 432 
in embryonic and adult skeletal muscle cells, and has been recently proposed as a 433 
possible regulator of satellite cell activation since BHLHB2 knockout mice exhibit 434 
increased cellular proliferation and degenerated myotubes during muscle 435 
regeneration process (48). BHLHB3 mRNA is expressed in proliferating C2C12 cells 436 
and is down-regulated during myogenic differentiation (2). Moreover, its 437 
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overexpression blocks myoblast to myotube differentiation in C2C12 cells, through 438 
either E-Box occupancy, direct interaction with MYOD1 protein, or both (3).  439 
In the present work we have demonstrated that both BHLHB2 and BHLHB3 440 
can inhibit muscle cell differentiation and induce myotube atrophy, reproducing the 441 
observed SREBP-1 effects in cultured muscle cells, notably a marked decrease in 442 
the expression of muscle specific transcription factors and sarcomeric proteins. 443 
Furthermore, silencing of BHLHB2 and BHLHB3 protein levels using siRNA fully 444 
restored the myogenic differentiation process in the presence of SREBP-1, and 445 
rescued, even if not completely, myotubes from atrophy induced by SREBP-1 446 
overexpression. These data therefore establish a novel regulatory pathway of muscle 447 
cell differentiation implicating SREBP-1, BHLHB2 and BHLHB3. Interestingly, it is 448 
also known that the transcriptional repressors BHLHB2 and BHLHB3 can antagonize 449 
each other’s effects (3, 32), and the scheme of this novel pathway can be completed 450 
with a negative feedback loop that has recently been described, in which both 451 
BHLHB2 and BHLHB3 inhibit SREBP-1c expression in a HIF-dependent mechanism 452 
(10). 453 
 454 
Muscle differentiation is under the control of two families of transcription 455 
factors, named Muscle Regulatory Factors (MRFs): the myogenic basic helix-loop-456 
helix (bHLH) proteins (i.e. MYF5, MYOD1, MYOG and MYF6), and the myocyte 457 
enhancer factor2 (MEF2) family of MADS domain-containing proteins (i.e. MEF2A, 458 
2B, 2C, and 2D) (5, 40). Moreover, the myogenic bHLH factors interact with MEF2 459 
proteins to cooperatively activate muscle specific genes (36). We have demonstrated 460 
here that nuclear accumulation of SREBP-1 proteins led to a coordinated inhibition of 461 
the expression of the MRF in myoblasts. This decrease, which results from 462 
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BHLHB2/B2 transcriptional repressors activation, is sufficient to explain the blockade 463 
of differentiation. How BHLHB2/B3 repress the expression of MRF remains to be 464 
precisely examined, but this may occur through competitive binding to E-Box on MRF 465 
promoters. Moreover, a direct interaction of the transcriptional repressors with MRF 466 
proteins may participate in the inhibition of differentiation, as already demonstrated 467 
with BHLHB3 and MYOD1 in C2C12 cells (3).  468 
 469 
Overexpression of SREBP-1 proteins, and also of BHLHB2/B3, induces both 470 
in vitro and in vivo myotube atrophy. The maintenance of muscle protein content 471 
results from intricately regulated anabolic and catabolic pathways. Examining genes 472 
regulated by both transcription factors reveals that MRFs and sarcomeric proteins 473 
are jointly down-regulated, whereas only SREBP-1 induce SMURF-1, an actor of the 474 
proteolytic pathway. The ubiquitin proteasome system has been described as the 475 
main regulator of muscle atrophy (30), and the role of SMURF1, FBXO32 (atrogin-1) 476 
and FOXO1 in this process has been recently reviewed (37). The marked reduction 477 
in sarcomeric protein, the induction of myotube atrophy, and the in vivo muscle 478 
wasting observed in the presence of SREBP-1 proteins could also have resulted from 479 
activation of this pathway. As the reversion of atrophy by BHLHB2/B3 silencing is 480 
only partial, a specific action of SREBP-1 proteins on the ubiquitin proteasome 481 
system involving other effectors than BHLHB2/B3 might thus be considered. 482 
Nevertheless, a significant part of the atrophic effect is due to BHLHB2/B3 action, 483 
through inhibition of sarcomeric proteins expression. This decrease in protein 484 
synthesis may be due to a direct action of BHLHB2/B3 on contractile protein 485 
promoters, or may also involve the decrease in MRFs expression. MRFs are still 486 
expressed in differentiated myotubes (50), and participate in the expression of 487 
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sarcomeric proteins (31). Whether MRFs are involved in the maintenance of the full 488 
diffentiated phenotype is still debated, but a combined decrease in MRFs expression 489 
in differentiated myotubes may affect muscle protein synthesis and thus participate in 490 
the observed atrophy. Further studies are needed to caracterize this atrophic process 491 
in terms of fiber type change, mitochondrial content, and oxidation capacity. 492 
 493 
The control of the amount of SREBP-1 proteins in the nucleus involves 494 
regulation at several levels, including SREBP-1 gene expression, proteolytic 495 
cleavage in the endoplasmic reticulum, nuclear import and activation/degradation 496 
within the nucleus (for review see (42)). It has been recently demonstrated that 497 
SREBP-1 expression is enhanced through the PKB/mTOR pathway, and could 498 
participate in the regulation of cell size through the control of lipid and cholesterol 499 
metabolism (41). The inflammatory cytokine TNF-alpha, which is known to induce 500 
muscle atrophy (33) has been shown to increase SREBP-1 levels in hepatocytes 501 
(15). Growth factors like insulin and IGF-1 are potent inducers of SREBP-1 502 
expression in various cell types and tissues (1, 13, 38). In muscle, SREBP-1c nuclear 503 
content can be dramatically increased by insulin through activation of both the 504 
PI3K/PKB (38) and the MAPK (28, 38) pathways. Furthermore, the SREBP-1 505 
proteins can control and enhance their own expression in human muscle cells (12). 506 
Due to the major and clearly demonstrated role of insulin, growth factors and the 507 
PI3K/PKB signaling pathway on muscle development and hypertrophy (23, 29), the 508 
atrophic effect of SREBP-1 proteins overexpression demonstrated in the present 509 
work likely represents a negative feedback loop to control muscle hypertrophy. In the 510 
same context, it is also interesting to notice that SREBP-1a and -1c enhance the 511 
expression of the p55 subunit of the PI3K (25, 43), which is regarded as a positive 512 
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regulator of the PI3K/PKB pathway (17). The SREBP-1 proteins may thus regulate 513 
the hypertrophic effects of growth factors not only negatively through induction of the 514 
BHLHB2 and BHLHB3 repressors, but also positively through the control of 515 
PI3K/PKB signaling pathway. Further investigations are required to study the impact 516 
of SREBP-1 on signaling pathways in skeletal muscle cells. 517 
 518 
In summary, the data presented here identify a new role for the SREBP-1 519 
transcription factors in the regulation of myogenesis and muscle tissue maintenance. 520 
As SREBP-1a and -1c are master regulators of fatty acids and cholesterol synthesis, 521 
this new function can justify to consider them as integrators of signals coming from 522 
growth factors, inflammation and nutritional status toward a control of muscle mass. It 523 
will therefore be of particular interest to further study these transcription factors in 524 
pathological situations inducing muscle wasting, but also in metabolic diseases 525 
where abnormalities in SREBP-1 have already been reported such as insulin-526 
resistance and type 2 diabetes. 527 
 528 
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Figure Legends 711 
 712 
Figure 1: BHLHB2 and B3 are up-regulated upon SREBP-1 overexpression 713 
(A) mRNA levels of BHLHB2 and BHLHB3 in myoblasts, myotubes and mouse TA 714 
muscle overexpressing GFP, SREBP-1a, SREBP-1c or ADD1-DN. (B) Protein levels 715 
of BHLHB2 and BHLHB3 in myotubes overexpressing GFP, SREBP-1a, SREBP-1c 716 
or ADD1-DN. Illustrative immunoblot on the left and quantification on the right. 717 
Coomassie blue (Coom) staining was used to normalize the total amount of proteins. 718 
Results are presented as mean ± SEM. * p 0,05 ; ** p0,001  (n= 3). 719 
 720 
Figure 2: BHLHB2 and B3 are SREBP-1 target genes 721 
BHLHB2 (A, left panel) and BHLHB3 (B, left panel) promoter activity in myoblasts 722 
(Mb), myotubes (Mt), and HEPG2 cells co-transfected with reporter gene plasmid 723 
pB22 or pB32 and expression vectors encoding either human SREBP-1a (pCDNA-724 
hSREBP1a) or SREBP-1c ( pCDNA-hSREBP1c) , or empty pCDNA3 as control. On 725 
the right panels, relative luciferase activity of constructs harboring mutations of SRE 726 
motifs identified in either BHLHB2 (A) or BHLHB3 (B) promoters. (C) Recruitment of 727 
SREBP1 on BHLHB2 and BHLHB3 promoters determined by ChIP experiments 728 
carried on insulin-treated HEK 293 cells. ChIP products were analysed by 729 
quantitative and classical PCR. Results are presented as mean ± SEM. * p 0,05 ; ** 730 
p0,001 (n=4). 731 
 732 
Figure 3: Common SREBP-1, BHLHB2 and B3 down-regulated muscle genes 733 
Venn diagram representing the distribution of SREBP-1, BHLHB2 and BHLHB3 734 
down- regulated genes corresponding to « Muscle development » (GO 0007517) (A) 735 
and to « Muscle contraction » (GO 0006936) (B). Overlapping genes are listed on the 736 
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right. 737 
 738 
Figure 4: SREBP1 and BHLHB2/B3 inhibit human myoblasts differentiation 739 
(A) mRNA levels of SREBP-1a, SREBP-1c, BHLHB2 and BHLHB3 in human primary 740 
muscle cells showing an increase during proliferation and a decrease after induction 741 
of differentiation. (B) mRNA levels of myogenic factors (MYOD, MEF2C, MYOG) in 742 
myoblasts overexpressing GFP, SREBP1a, or SREBP1c. (C) Representative phase 743 
contrast images of myoblasts overexpressing GFP, SREBP1a, or SREBP1c after 5 744 
days of differentiation (Scale bar = 100µm). (D) mRNA levels of myogenic factors 745 
(MYOD, MEF2C, MYOG) in myoblasts overexpressing GFP, BHLHB2, or BHLHB3. 746 
(E) Representative images of myoblasts overexpressing GFP, BHLHB2, or BHLHB3 747 
after 5 days of differentiation (Scale bar = 100µm); Myogenin (MYOG) and Troponin 748 
I1 (TNNI1) immunostaining (red), with DAPI staining (blue), were performed to 749 
assess differentiation state. Results are presented as mean ± SEM. * p 0,05 ; ** 750 
p0,001, (n=3). 751 
 752 
Figure 5: SREBP-1 inhibit human myoblasts differentiation through BHLHB2/B3 753 
repressors 754 
Human myoblasts were infected for 48 h with recombinant adenoviruses encoding 755 
SREBP-1a, or SREBP-1c, or GFP and co-transfected for 72h with siRNA against 756 
BHLHB2 or BHLHB3 or both, or with siRNA against GFP as control. Representative 757 
immunoblot of BHLHB2 and BHLHB3 (A) and MYOD1, MYOG and MEF2C (B) in 758 
myoblasts transfected with siRNA against GFP (lanes 1) BHLHB2 (lanes 2) or 759 
BHLHB3 (lanes 3), and quantification of the protein levels (right panels). Coomassie 760 
blue (Coom) staining was used to normalize the total amount of proteins. Results are 761 
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presented as mean ± SEM. * p 0,05 ; ** p0,001, (n=3). (C) Representative images 762 
of myoblasts overexpressing GFP, SREBP-1a or SREBP-1c, and transfected with 763 
siRNA against GFP (line 1) BHLHB2 (line 2) BHLHB3 (line 3) and both BHLHB2 and 764 
BHLHB3 (line 4) after 5 days of differentiation (Scale bar = 100µm); Myogenin 765 
(MYOG, left) and Troponin I1 (TNNI1, right) immunostaining (red), with DAPI staining 766 
(blue) were performed to assess differentiation state. 767 
 768 
Figure 6: SREBP-1 induce human myotubes atrophy 769 
Human myotubes were infected for 48 h with recombinant adenoviruses encoding 770 
GFP, SREBP-1a, or SREBP-1c. (A) mRNA levels of myogenic factors (MYOD1, 771 
MEF2C, MYOG), sarcomeric proteins (MYL1, TNN, TNNI1 or TNNI2),  and atrogenic 772 
factors (FOXO1, FBXO32, SMURF1) (n= 6 in each group). (B) Protein levels of 773 
SREBP1, MYOD1, MYOG, MEF2C, TNNI1 and TNNI2; Coomassie blue (Coom) 774 
staining was used to normalize the total amount of proteins (n= 4 in each group). (C) 775 
Representative images of myotubes overexpressing GFP, SREBP-1a, SREBP-1c 776 
and ADD1-DN (Scale bar = 100µm); upper panels: phase contrast images; lower 777 
panels: immunostaining with TNNI1 antibody (red) and DAPI staining (blue). (D) 778 
Measurement of the area of myotubes overexpressing GFP, SREBP-1a and SREBP-779 
1c stained with TNNI1 antibody (n= 3 in each group). 780 
Results are presented as mean ± SEM. * p 0,05 ; ** p0,001.  781 
 782 
Figure 7: SREBP-1 induce myotubes atrophy through BHLHB2/B3 repressors 783 
Human myotubes were infected for 48 h with recombinant adenoviruses encoding 784 
GFP, BHLHB2, or BHLHB3. (A) mRNA levels of myogenic factors (MYOD1, MEF2C, 785 
MYOG), sarcomeric proteins (MYL1, TNN, TNNI1), and atrogenic factors (FOXO1, 786 
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FBXO32, SMURF1). (B) Representative images of myotubes overexpressing GFP, 787 
BHLHB2 and BHLHB3. Upper panels: phase contrast, lower panels: immunostaining 788 
with TNNI1 antibody (red) and DAPI staining (blue) (Scale bar = 100µm). (C) 789 
Measurement of the aera of myotubes overexpressing GFP, BHLHB2 or BHLHB3 790 
immunostained with TNNI1 antibody (n= 3 in each group). Results are presented as 791 
mean ± SEM. * p 0,05 ; ** p0,001. (D) Representative images of myotubes 792 
overexpressing GFP, SREBP-1a or SREBP-1c, and transfected with siRNA against 793 
GFP (lane 1), BHLHB2 (lane 2), and BHLHB3 (lane 3) for 48 hours (Scale bar = 794 
100µm). (E) Measurement of the area of myotubes overexpressing GFP, SREBP-1a 795 
and SREBP-1c and transfected with siRNA against GFP, BHLHB2 or BHLHB3. 796 
Myotubes were stained with TNNI1 antibody (n= 3 in each group). 797 
Results are presented as mean ± SEM. * p 0,05 ; ** p0,001.  798 
 799 
Figure 8: In vivo overexpression of SREBP-1 leads to muscle atrophy 800 
Tibialis Anterior (TA) muscles of mice were injected with recombinant adenovirus Ad-801 
GFP, Ad-SREBP-1a/GFP, Ad- SREBP-1c/GFP, Ad-BHLHB2 or Ad-BHLHB3. (A) TA 802 
weight 7 days after adenoviral infection (n= 7 in each group). (B) Mean CSA of TA 803 
fibers. (C) Distribution of mean CSA of TA muscle fibers (n=4 in each group). (D) 804 
Representative images of TA sections, expressing GFP, or SREBP-1a and GFP, or 805 
SREBP-1c and GFP: DAPI staining (blue) and GFP fluorescence (green) (Scale bar 806 
= 100 µm). (E) Distribution of CSA of TA muscle fibers as a function of myofiber 807 
fluorescence. Results are presented as mean ± SEM. ** p 0,001; *** p0,0001 808 
(n=4). 809 
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Table 1: Muscle specific SREBP-1 target genes 810 
Listing of 1300 SREBP-1 targets genes identified previously (43) was analysed using 811 
FATIGO+. Three GO classes were found to be statistically over-represented: muscle 812 
contraction (GO 0006936, adjusted p value = 1.66 e-4), striated muscle contraction 813 
(GO 0006941, adjusted p value = 7.29 e-5) and muscle development (GO 0007517, 814 
adjusted p value = 6,51 e-5). 815 
 816 
Symbol LLID Fold 1A Fold 1C Name 
    
 
GO 0006936 : Muscle contraction (Adjusted p value : 2.84 e-5) 
    
 
ADRB2 154 -2.48 -2.61 Adrenergic, beta-2-, receptor, surface 
ALDOA 226 2.06  Aldolase A, fructose-bisphosphate 
ATP1A1 476 -2.27  ATPase. Na+/K+ transporting. alpha 1 polypeptide 
ATP1A2 477 -2.31  ATPase. Na+/K+ transporting. alpha 2 (+) polypeptide 
ATP2A2 488 -1.86  ATPase. Ca++ transporting. cardiac muscle. slow twitch 2 
CACNG1 786 -7.42  Calcium channel. voltage-dependent. gamma subunit 1 
CASQ2 845 -3.45  Calsequestrin 2 (cardiac muscle) 
CHRNA1 1134 -1.96  Cholinergic receptor. nicotinic. alpha 1 (muscle) 
DTNA 1837 -4.02 -3.01 Dystrobrevin, alpha 
EDNRA 1909 -3.21  Endothelin receptor type A 
FXYD1 5348  3.31 FXYD domain containing ion transport regulator 1 (phospholemman) 
GAL 2660 4.28  Galanin 
GJA1 2697 -4.83 -2.02 Gap junction protein. alpha 1. 43kDa (connexin 43) 
HRC 3270 -2.72  Histidine rich calcium binding protein 
ID2B 84099 -1.60  Inhibitor of DNA binding 2B. dominant negative helix-loop-helix protein 
KBTBD10 10324  -1.60 Kelch repeat and BTB (POZ) domain containing 10 
KCNH2 3757 -1.73  Potassium voltage-gated channel. subfamily H (eag-related). member 2 
MRCL3 10627  -1.63 Myosin regulatory light chain MRCL3 
MYBPC1 4604 -4.62  Myosin binding protein C. slow type 
MYBPC2 4606 14.91 10.04 Myosin binding protein C. fast type 
MYBPH 4608 -19.98  Myosin binding protein H 
MYH2 4620 -6.45  Myosin. heavy polypeptide 2. skeletal muscle. adult 
MYH3  80184 16.48  Myosin. heavy polypeptide 3 
MYH6 4624  3.47 myosin. heavy polypeptide 6. cardiac muscle. alpha 
MYH8 4626 -8.82 -2.39 Myosin. heavy polypeptide 8. skeletal muscle. perinatal 
SCN7A 6332 2.64  Sodium channel. voltage-gated. type VII. alpha 
SLC6A8 6535 -1.47  Solute carrier family 6 (neurotransmitter transporter, creatine), member 8 
SMPX 23676 -8.55  Small muscle protein, X-linked 
SNTA1 6640 1.70  Syntrophin, alpha 1 (dystrophin-associated protein A1) 
SSPN 8082 -3.15  Sarcospan (Kras oncogene-associated gene) 
TNNC2 7125 -2.83  Troponin C type 2 (fast) 
TNNI1 7135 -2.32  Troponin I type 1 (skeletal. slow) 
TNNI2 7136 -3.07  Troponin I type 2 (skeletal. fast) 
TNNT2 7139 -1.88  Troponin T type 2 (cardiac) 
TNNT3 7140 -2.83  Troponin T type 3 (skeletal. fast) 
TPM1 7168 -4.54  Tropomyosin 1 (alpha) 
TPM3 7170  -2.44 Tropomyosin 3 
TTN 7273 1.92 2.93 Titin 
     
GO 0007517 : Muscle development (Adjusted p value : 6.27 e-5) 
     
ACTG1 71 -2.86 -2.37 Actin, gamma 1 
AEBP1 165 2.29  AE binding protein 1 
CAV3 859 -1.94  Caveolin 3 
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COL5A3 50509 -1.53  Collagen. type V. alpha 3 
COL6A3 1293 1.40  Collagen. type VI. alpha 3 
CSRP2 1466 -4.25  Cysteine and glycine-rich protein 2 
CUGBP2 10659 -1.80  CUG triplet repeat, RNA binding protein 2 
DSCR1 1827 -2.18 -1.78 Down syndrome critical region gene 1 
EVC 2121 -1.50  Ellis van Creveld syndrome 
FHL1 2273 -4.99  Four and a half LIM domains 1 
FXYD1 5348  3.31 FXYD domain containing ion transport regulator 1 (phospholemman) 
GDF8 2660 -6.20 -1.98 Growth differentiation factor 8 (myostatin) 
HBEGF 1839 5.22 4.10 Heparin-binding EGF-like growth factor 
HDAC5 10014 2.35  Histone deacetylase 5 
HDAC9 9734 -2.15  Histone deacetylase 9 
HSBP2 3316 -3.37  Heat shock 27kDa protein 2 
ITGA7 3679 -2.40  Integrin. alpha 7 
ITGB1BP2 26548 -4.72  Integrin beta 1 binding protein (melusin) 2 
KRT19 3880 2.50  Keratine 19 
MEF2C 4208 -6.73 -3.45 Myocyte Enhancer Factor 2C) 
MLLT7 4303 1.96 3.40 Myeloid/lymphoid or mixed-lineage leukemia 
MRAS 22808 -3.86 -2.03 Muscle RAS oncogene homolog 
MYH6 4624  3.47 Myosin. heavy polypeptide 6. cardiac muscle. alpha 
MYH10 4628 2.28  Myosin, heavy polypeptide 10, non-muscle 
MYL1 4632 -4.16  Myosin. light polypeptide 1. alkali; skeletal. fast 
MYL4 4635  2.28 Myosin. light polypeptide 4. alkali; atrial. embryonic 
MYOD1 4654 -2.76  Myogenic differentiation 1 
MYOG 4656 -7.42  Myogenin (myogenic factor 4) 
NRD1 4898 3.97 2.59 Nardilysin (N-arginine dibasic convertase) 
SGCD 6444 -5.09  Sarcoglycan. delta (35kDa dystrophin-associated glycoprotein) 
SGCG 6445 -2.42  Sarcoglycan. gamma (35kDa dystrophin-associated glycoprotein) 
SIX1 6495 -3.88 -2.85 Sine oculis homeobox homolog 1 (Drosophila) 
SMAD3 4088 -1.82 -1.78 SMAD, mothers against DPP homolog 3 
SNTA1 6640 1.70  Syntrophin, alpha 1 (dystrophin-associated protein A1) 
TEAD4 7004 -3.54  TEA domain family member 4 
TMOD1 7111 -3.01  Tropomodulin 1 
TNNT2 7139 -1.88  Troponin T type 2 (cardiac) 
TTN 7273 1.92 2.93 Titin 
VAMP5 10791 -3.03  Vesicle-associated membrane protein 5 (myobrevin) 
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Table2: Muscle specific BHLHB2/B3 target genes  818 
Microarray analysis was performed on human primary muscle cells overexpressing 819 
either BHLHB2 or BHLHB3. Listing of BHLHB2/B3 identified target genes was 820 
analysed using FATIGO+. Biological processes “muscle contraction”, “striated 821 
muscle contraction” and muscle development” show significant enrichment (adjusted 822 
p value < 0.05). 823 
 824 
LLID Symbol Fold B2 Fold B3 Gene name 
58 ACTA1 -2,89 -4,55 Actin, alpha 1, skeletal muscle 
70 ACTC -1,78 -2,75 Actin, alpha, cardiac muscle 
88 ACTN2 -1,69  Actinin, alpha 2 
89 ACTN3 -2,67 -3,27 Actinin, alpha 3 
203 AK1 -1,56 -2,19 Adenylate kinase 1 
10930 APOBEC2  -1,76 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2 
57679 ALS2 1,75  Amyotrophic lateral sclerosis 2 (juvenile) 
130540 ALS2CR12 1,41  Amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 12 
26287 ANKRD2 -1,52  Ankyrin repeat domain 2 (stretch responsive muscle) 
316 AOX1 1,51  Aldehyde oxidase 1 
487 ATP2A1 -1,83  ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 
444 ASPH  1,57 Aspartate beta-hydroxylase 
79888 AYTL2 1,80  Acyltransferase like 2 
8678 BECN1 1,36  Beclin 1 (coiled-coil, myosin-like BCL2 interacting protein) 
779 CACNA1S -1,36 -1,68 Calcium channel, voltage-dependent, L type, alpha 1S subunit 
782 CACNB1 -2,85  Calcium channel, voltage-dependent, beta 1 subunit 
786 CACNG1 -2,06 -5,29 Calcium channel, voltage-dependent, gamma subunit 1 
823 CAPN1 1,37  Calpain 1, (mu/I) large subunit 
84698 CAPS2 1,34  Calcyphosine 2 
859 CAV3 -1,73 -3,44 Caveolin 3 
928 CD9 1,96  CD9 molecule 
1013 CDH15  -2,07 Cadherin 15, M-cadherin (myotubule) 
50937 CDON -1,59 -2,79 Cdon homolog (mouse) 
1072 CFL1 -1,38  Cofilin 1 (non-muscle) 
1134 CHRNA1 -1,71  Cholinergic receptor, nicotinic, alpha 1 (muscle) 
1146 CHRNG -2,34 -2,31 Cholinergic receptor, nicotinic, gamma 
1152 CKB -1,42  Creatine kinase, brain 
1158 CKM -2,33 -2,90 Creatine kinase, muscle 
1160 CKMT2 -4,09 -3,86 Creatine kinase, mitochondrial 2 (sarcomeric) 
50509 COL5A3 -1,74 -1,62 Collagen, type V, alpha 3 
1339 COX6A2 -1,55  Cytochrome c oxidase subunit VIa polypeptide 2 
1410 CRYAB -2,02 -2,12 Crystallin, alpha B 
1674 DES -1,58 -1,80 Desmin 
25891 DKFZP586H2123 1,35  Regeneration associated muscle protease 
1760 DMPK -1,97 -2,84 Dystrophia myotonica-protein kinase 
1837 DTNA  1,89 Dystrobrevin, alpha 
1838 DTNB  -1,49 Dystrobrevin, beta 
8291 DYSF  -1,59 Dysferlin, limb girdle muscular dystrophy 2B (autosomal recessive) 
1917 EEF1A2 -1,98 -2,26 Eukaryotic translation elongation factor 1 alpha 2 
112399 EGLN3   Egl nine homolog 3 (C. elegans) 
2027 ENO3 -1,82 -1,91 Enolase 3 (beta, muscle) 
114907 FBXO32 2,07  F-box protein 32 
2281 FKBP1B  2,16 FK506 binding protein 1B, 12.6 kDa 
2318 FLNC  -2,30 Filamin C, gamma (actin binding protein 280) 
2308 FOXO1 -1,46 -2,20 Forkhead box O1 
2660 GDF8 2,18  Gap junction protein, alpha 1, 43kDa (connexin 43) 
93626 GNA11 1,34  guanine nucleotide binding protein (G protein), alpha 11 (Gq class) 
2997 GYS1 -1,83  Glycogen synthase 1 (muscle) 
9759 HDAC4 -1,57 -1,69 Histone deacetylase 4 
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3270 HRC -1,58 -1,68 Histidine rich calcium binding protein 
3679 ITGA7  -1,59 Integrin, alpha 7 
10324 KBTBD10 1,86  Kelch repeat and BTB (POZ) domain containing 10 
3939 LDHA -1,55  Lactate dehydrogenase A 
6300 MAPK12 -1,97 -2,85 Mitogen-activated protein kinase 12 
4151 MB -1,90 -1,52 Myoglobin 
10150 MBNL2 1,57  Muscleblind-like 2 (Drosophila) 
4208 MEF2C  -1,95 
MADS box transcription enhancer factor 2, polypeptide C (myocyte 
enhancer factor 2C) 
22808 MRAS  -2,11 Muscle RAS oncogene homolog 
23164 M-RIP  -1,84 Myosin phosphatase-Rho interacting protein 
103910 MRLC2 1,57  Myosin regulatory light chain MRLC2 
136319 MTPN 1,76  Myotrophin 
4604 MYBPC1 -1,69  Myosin binding protein C, slow type 
4608 MYBPH  -2,69 Myosin binding protein H 
4620 MYH2 -1,76  Myosin, heavy polypeptide 2, skeletal muscle, adult 
80184 MYH3 (CEP290) -1,69 -3,82 Myosin, heavy polypeptide 3 
4624 MYH6 -1,41 -1,71 myosin, heavy polypeptide 6, cardiac muscle, alpha 
4625 MYH7 -1,70 -3,28 Myosin, heavy chain 7, cardiac muscle, beta 
8735 MYH13 -1,42  Myosin heavy chain 13  
4632 MYL1 -1,41  Myosin, light polypeptide 1, alkali; skeletal, fast 
4633 MYL2 -1,81 -2,23 Myosin, light chain 2, regulatory, cardiac, slow 
4634 MYL3 -1,69 -1,72 Myosin, light chain 3, alkali; ventricular, skeletal, slow 
4636 MYL5 -1,84  Myosin, light chain 5, regulatory 
93408 MYLC2PL 1,31  Myosin light chain 2, precursor lymphocyte-specific 
85366 MYLK2 1,33  Myosin light chain kinase 2, skeletal muscle 
53904 MYO3A 1,48  Myosin IIIA 
4645 MYO5B -1,54  myosin VB [GDB] 
4654 MYOD1 -1,71  Myogenic differentiation 1 
4656 MYOG -1,91 -5,79 Myogenin (myogenic factor 4) 
9172 MYOM2 -3,03 -3,11 Myomesin (M-protein) 2, 165kDa 
9499 MYOT -2,95 -3,67 Myotilin 
84665 MYPN -1,60  Myopalladin 
4692 NDN  1,44 Necdin homolog (mouse) 
4703 NEB  -1,72 Nebulin 
84033 OBSCN -1,39 -2,46 Obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF 
55229 PANK4 -1,32  Pantothenate kinase 4 
5081 PAX7 -1,42  Paired box 7 
5213 PFKM -1,48  Phosphofructokinase, muscle 
5224 PGAM2 -2,57 -2,60 Phosphoglycerate mutase 2 (muscle) 
64091 POPDC2  -1,36 Popeye domain containing 2 
64208 POPDC3  -1,78 Popeye domain containing 3 
10891 PPARGC1A -2,32  Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha 
4659 PPP1R12A 1,45  Protein phosphatase 1, regulatory (inhibitor) subunit 12A 
53632 PRKAG3 -2,16 -6,45 Protein kinase, AMP-activated, gamma 3 non-catalytic subunit 
89970 RSPRY1 -1,43  Ring finger and SPRY domain containing 1 
6415 SEPW1 -1,40 -1,48 Selenoprotein W, 1 
6444 SGCD -1,61 -1,39 Sarcoglycan, delta (35kDa dystrophin-associated glycoprotein) 
6445 SGCG  -1,96 Sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) 
6526 SLC5A3 -1,93  sodium/myo-inositol cotransporter 1  
6535 SLC6A8  -1,59 Solute carrier family 6 (neurotransmitter transporter, creatine), member 8 
6586 SLIT3  -3,95 Slit homolog 3 (Drosophila) 
6641 SNTB1  -1,92 
Syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, basic 
component 1) 
8878 SQSTM1 1,52  Sarcospan (Kras oncogene-associated gene) 
8082 SSPN  -1,69 Sarcospan (Kras oncogene-associated gene) 
6840 SVIL 1,52 -1,39 Titin-cap (telethonin) 
23345 SYNE1  1,40 Supervillin 
8557 TCAP -1,80  Spectrin repeat containing, nuclear envelope 1 
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7004 TEAD4 -2,37 -4,18 TEA domain family member 4 
7111 TMOD1  -2,13 Tropomodulin 1 
29766 TMOD3 1,66 1,49 Tropomodulin 3 (ubiquitous) 
7134 TNNC1  -1,59 Troponin C type 1 (slow) 
7135 TNNI1 -2,46 -2,34 Troponin I type 1 (skeletal, slow) 
7136 TNNI2 -1,40 -1,52 Troponin I type 2 (skeletal, fast) 
7139 TNNT2 -1,48 -2,12 Troponin T type 2 (cardiac) 
7140 TNNT3 -2,07 -2,13 Troponin T type 3 (skeletal, fast) 
57159 TRIM54  -1,79 Tripartite motif-containing 54 
84675 TRIM55 -1,61 -2,56 Tripartite motif-containing 55 
84676 TRIM63 -3,91 -4,12 Tripartite motif-containing 63 
7273 TTN -1,90 -4,98 Titin 
81622 UNC93B1 -1,78  Unc-93 homolog B1 (C. elegans) 
7431 VIM 1,82  Vimentin 
 825 
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